{"id":560766,"date":"2026-07-21T12:30:00","date_gmt":"2026-07-21T10:30:00","guid":{"rendered":"https:\/\/medizinonline.com\/?p=560766"},"modified":"2026-07-21T16:15:02","modified_gmt":"2026-07-21T14:15:02","slug":"los-quelantes-de-potasio-como-factores-que-facilitan-la-optimizacion-del-raasi","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/es\/los-quelantes-de-potasio-como-factores-que-facilitan-la-optimizacion-del-raasi\/","title":{"rendered":"Los quelantes de potasio como factores que facilitan la optimizaci\u00f3n del RAASi"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Los inhibidores del sistema renina-angiotensina-aldosterona (RAASi) \u2014incluidos los antagonistas de los receptores de los mineralocorticoides (MRA)\u2014 se encuentran entre los pilares m\u00e1s eficaces de la medicina cardiorrenal. Sin embargo, su utilidad se ve a menudo mermada en la pr\u00e1ctica cl\u00ednica diaria, ya que el temor a la hiperpotasemia conduce a una reducci\u00f3n de la dosis o a la interrupci\u00f3n del tratamiento. Con los nuevos captadores de potasio, el patir\u00f3mero y el ciclosilicato de sodio y circonio (SZC), se dispone por primera vez de una estrategia bien estudiada capaz de superar precisamente esta limitaci\u00f3n: no reducir el potasio por el simple hecho de hacerlo, sino permitir y mantener el tratamiento con inhibidores del RAAS, que prolonga la vida. El r\u00e1pido auge de la finerenona \u2014con la hiperpotasemia como se\u00f1al de seguridad fundamental\u2014 confiere a este tema una nueva urgencia cl\u00ednica.   <\/strong><\/p>\n\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/es\/mi-cuenta\/paquetes\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">\u00bfYa eres miembro? <a href=\"https:\/\/medizinonline.com\/es\/conectarse\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Fes%2Flos-quelantes-de-potasio-como-factores-que-facilitan-la-optimizacion-del-raasi%2F\">Accede aqu\u00ed<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>Los inhibidores del sistema renina-angiotensina-aldosterona (RAASi) \u2014incluidos los antagonistas de los receptores de los mineralocorticoides (MRA)\u2014 se encuentran entre los pilares m\u00e1s eficaces de la medicina cardiorrenal. Sin embargo, su&#8230;&hellip;... <\/p>\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/es\/mi-cuenta\/paquetes\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">\u00bfYa eres miembro? <a href=\"https:\/\/medizinonline.com\/es\/conectarse\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Fes%2Flos-quelantes-de-potasio-como-factores-que-facilitan-la-optimizacion-del-raasi%2F\">Accede aqu\u00ed<\/a><\/div><\/div><\/div>","protected":false},"author":7,"featured_media":560767,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Por qu\u00e9 el auge de la finerenona confiere una nueva relevancia al tratamiento de la hiperpotasemia","footnotes":"","_members_access_role":[],"_members_access_error":""},"category":[11552,11324,11475,11478,11288,11377],"tags":[95520,68041,17129],"powerkit_post_featured":[],"class_list":["post-560766","post","type-post","status-publish","format-standard","has-post-thumbnail","category-rx-es","category-cardiologia","category-estudios","category-formacion-continua","category-medicina-interna-general","category-nefrologia","tag-agente-de-fijacion-de-potasio","tag-finerenon-es","tag-hiperpotasemia","pmpro-level-required","pmpro-level-1","pmpro-no-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-08-12 04:06:01","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"es_ES","wpml_translations":[],"_links":{"self":[{"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/posts\/560766","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/comments?post=560766"}],"version-history":[{"count":1,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/posts\/560766\/revisions"}],"predecessor-version":[{"id":560768,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/posts\/560766\/revisions\/560768"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/media\/560767"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/media?parent=560766"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/category?post=560766"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/tags?post=560766"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/powerkit_post_featured?post=560766"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}